洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

【ChiCTR2200063518】Enhancing global self-esteem of breast cancer survivors: a randomized controlled trial

基本信息
登记号

ChiCTR2200063518

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2022-09-09

临床申请受理号

/

靶点

/

适应症

Breast cancer

试验通俗题目

Enhancing global self-esteem of breast cancer survivors: a randomized controlled trial

试验专业题目

Enhancing global self-esteem of breast cancer survivors: a randomized controlled trial

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

联系人通讯地址
临床试验信息
试验目的

To evaluate a Tai Chi program for breast cancer survivors on self-esteem and physical health.

试验分类
试验类型

随机平行对照

试验分期

其它

随机化

Participants will be block-randomized (block size=15) to each treatment group in a 1:1:1 ratio. Allocation will be determined by a computer-generated random sequence prepared by a statistician not be involved in this study.

盲法

Participants and outcome assessors will be blinded from the treatment group allocation.

试验项目经费来源

General Research Grant from Research Grans Council

试验范围

/

目标入组人数

75

实际入组人数

/

第一例入组时间

2023-01-01

试验终止时间

2025-06-01

是否属于一致性

/

入选标准

1. Women aged >18 years; 2. Diagnosed with Stage I–III breast cancer within the past 5 years; 3. Completed adjuvant treatment (chemotherapy and/or radiation therapy) at least 1 year before study commencement; 4. Receiving hormone therapy; 5. Have ≥ any two CVD risks: overweight/obesity, high blood pressure, hyperglycaemia, hyperlipidaemia, physical inactivity (i.e. <150min moderate-intensity exercise/week) and smoking; 6. Able to understand and speak Cantonese; 7. Able to give informed consent.;

排除标准

1. Diagnosed with any CVD; 2. Concurrently participating in other organized lifestyle, dietary or weight control intervention programs; 3. Physically unfit for exercise as indicated by the results of Physical Activity Readiness Questionnaire during recruitment.;

研究者信息
研究负责人姓名
试验机构

Research Grants Council Hong Kong

研究负责人电话
研究负责人邮箱
研究负责人邮编

/

联系人通讯地址
<END>

The Nethersole School of Nursing, The Chinese University of Hong Kong的其他临床试验

最新临床资讯

对摩熵医药数据库感兴趣,可以免费体验产品